Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

By S. Shangary, Dongguang Qin, D. McEachern, Meilan Liu, Rebecca S Miller, S. Qiu, Zaneta Nikolovska-Coleska, Ke Ding, Guoping Wang, Jianyong Chen and 12 more. Proceedings of the National Academy of Sciences of the United States of America, 2008

654 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/b208b01d6c9dc8e3152bbea9f0c3b42546145741

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Wenyi Wei
2. David P. Lane
3. Lei Chen
4. Alan R. Fersht
5. T. Meng
6. Ping Wang
7. Lu Deng
8. Shaomeng Wang

In Oncology

1. David P. Lane
2. Alan R. Fersht

Citations in the corpus

• Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials (2020, background): “Therefore, recovering the impaired the function of p53 by disrupting the MDM2/p53 interaction offers a potential approach for the treatment of cancer.(68,69) The X-ray crystallography disclosed the details of the MDM2/ p53 interaction.”
• The role of ubiquitination in tumorigenesis and targeted drug discovery (2020, background): “For example, MI-219 is an orally available compound with a subnanomolar affinity for Mdm2 and can increase the expression of p53 and p53-targeted genes.(384) In addition, other small molecules, which include HLI98,(388) HLI373,(389) MEL24 (ref.”
• Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy (2009, methodology): “Studies using Nutlin-3 and MI-219 show that MDM2 inhibitors yield both common and different cellular responses in normal and tumor cells (32,35).”
• Awakening guardian angels: drugging the p53 pathway (2009, background): “In the second approach, inhibitors of the protein–protein interaction of p53 with the negative regulator MDM2 have been developed that show clear anti-tumour activity in preclinical animal model”